This clinical trial is focused on studying a condition known as elevated lipoprotein(a), which is a type of lipoprotein disorder. Lipoproteins are particles in the blood that carry cholesterol and other fats. When levels of lipoprotein(a) are high, it can increase the risk of heart disease. The study is testing a new treatment called LY3819469, which is a solution for injection developed by Eli Lilly and Company. This treatment is being compared to a placebo to see if it can effectively reduce the levels of lipoprotein(a) in the blood.

The purpose of the study is to determine if LY3819469 is better than a placebo in lowering lipoprotein(a) levels. Participants in the study will receive either the treatment or a placebo through an injection under the skin, known as a subcutaneous injection. The study will last for a period of time, during which participants will be monitored to see how their lipoprotein(a) levels change. The maximum daily dose of the treatment is 400 milligrams, and the total dose over the course of the study can be up to 800 milligrams.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable information on the safety and effectiveness of LY3819469 for people with elevated lipoprotein(a) levels, potentially leading to new treatment options for this condition.